Related Experiment Videos
Meningococcal disease as a model to evaluate novel anti-sepsis strategies
1Department of Infectious Diseases & Microbiology, Imperial College School of Medicine at Hammersmith Hospital, London, England.
Objective:
To consider the appropriateness of meningococcemia as a clinical entity for the evaluation of anti-endotoxin agents.
Data Sources:
English language published literature concerning meningococcemia, sepsis, and endotoxin.
Study Selection:
The purpose of this work is to consider some of the practical and scientific issues that arise in designing clinical trials to evaluate anti-endotoxin agents. A selected review of recently published articles was undertaken.
Data Extraction And Synthesis:
Relevant literature has been cited to support factual statements in the text.
Conclusion:
Meningococcemia as a paradigm of endotoxin-mediated Gram-negative sepsis has many advantages. It is a homogeneous population, and it represents a single, measurable, bacterial target that is unequivocally implicated in the pathogenesis of the disease. However, it is an uncommon disease that may develop so quickly that attempts to intervene may be too late to have an effect. There is considerable morbidity, but how best to measure the outcome and the extent to which the results can be extrapolated to adult populations with sepsis secondary to nosocomial infection remain unclear.
Insights
Meningococcemia is a suitable model for evaluating anti-endotoxin therapies due to its clear bacterial target. However, its rarity and rapid progression pose challenges for clinical trials in sepsis.
Area of Science:
- Clinical microbiology
- Pharmacology
- Infectious diseases
Background:
- Meningococcemia serves as a model for Gram-negative sepsis.
- Endotoxin plays a key role in the pathogenesis of sepsis.
Purpose of the Study:
- To evaluate meningococcemia as a clinical model for assessing anti-endotoxin agents.
- To explore challenges in designing clinical trials for anti-endotoxin therapies.
Main Methods:
- Literature review of meningococcemia, sepsis, and endotoxin.
- Analysis of practical and scientific issues in clinical trial design.
Main Results:
- Meningococcemia offers a homogeneous population and a single bacterial target.
- The disease's rapid onset may limit the efficacy of interventions.
- Outcome measurement and extrapolation to adult sepsis populations require further clarification.
Conclusions:
- Meningococcemia is a valuable, albeit imperfect, model for studying endotoxin-mediated sepsis.
- Further research is needed to optimize clinical trial designs and outcome measures for anti-endotoxin agents.